This article was downloaded by:


On: 26 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

Mechanistic Similarities Between Thymidylate Synthase and IMP Dehydrogenase: A Common Strategy of Catalysis

T. I. Kalman^a

^a Department of Medicinal Chemistry, State University at New York, Buffalo, New York, USA

To cite this Article Kalman, T. I.(1999) 'Mechanistic Similarities Between Thymidylate Synthase and IMP Dehydrogenase: A Common Strategy of Catalysis', Nucleosides, Nucleotides and Nucleic Acids, 18:4,845-846

To link to this Article: DOI: 10.1080/15257779908041577 URL: http://dx.doi.org/10.1080/15257779908041577

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

MECHANISTIC SIMILARITIES BETWEEN THYMIDYLATE SYNTHASE AND IMP DEHYDROGENASE: A COMMON STRATEGY OF CATALYSIS

T. I. Kalman*

State University at New York, Department of Medicinal Chemistry, 457 Cooke Hall, Buffalo, New York 14260, USA

Thymidylate synthase (TS) and inosine 5'-monophosphate dehydrogenase (IMPDH) are important targets of drug action and development. The two enzymes bear no structural resemblance to each other and they catalyze fundamentally different chemical reactions:

$$dUMP + 5,10$$
-methylenetetrahydrofolate ===> $dTMP + dihydrofolate$ (TS)
 $IMP + NAD^+ + H_2O$ ===> $XMP + NADPH + H^+$ (IMPDH)

Therefore, it is surprising that TS and IMPDH appear to share many mechanistic features. Whereas TS has been studied extensively in many laboratories¹ and its mechanism described in detail^{1,2}, the information about the structure and mechanism of IMPDH is limited^{3,4}. Nevertheless, there are sufficient data available that permitted the recognition of many striking mechanistic similarities: (1) both enzymes initiate catalysis by nucleophilic addition of the sulfhydryl group of an active site cysteine residue to the conjugated carbonyl system of the heterocyclic base of the substrate; (2) all chemical transformations are carried out while the nucleotide is covalently attached to the enzyme *via* a thioether linkage; (3) hydride transfer occurs between substrate and cofactor; (4) covalently bound enolate intermediates are involved; (5) sp² <=> sp³ rehybridizations take place at the position of substitution of the substrate (C-5 for TS and C-2 for IMPDH), where a hydrogen is displaced during the reaction; (6) dehalogenations are catalyzed by both TS (5-bromo- and 5-iodo-dUMP) and IMPDH (2-chloro- and 2-fluoro-IMP); (7) the nucleotide substrate binds before the cofactor, which stacks on the purine or pyrimidine

846 KALMAN

ring in a parallel plane to facilitate hydride transfer; (8) a 'flap' covers the active site during catalysis requiring a large conformational change.

Interestingly, the similarities extend beyond the active sites: (1) both enzymes use

nucleoside 5'-monophosphates as substrates, which are converted to a unique purine or pyrimidine nucleotide, as part of *de novo* biosynthesis; (2) both enzymes utilize cofactors, which require regeneration by separate redox enzymes. Some of these similarities permit analogous rationales for inhibitor design, which should aid drug development.

REFERENCES

- 1. Carreras, W. C., Santi, D. V. Annu. Rev. Biochem., 1995, 64, 721-762.
- 2. Kalman, T. I., Matthews, D. A. This volume.
- Whitby, F. G., Luecke, H., Kuhn, P., Somoza, J. R., Huete-Perez, J. A., Philips, J. D., Hill, C. P., Fletterick, R. J., Wang, C. C. Biochemistry, 1997, 36, 10666-10674.